Operations
Updesh Dosanjh, practice leader of technology solutions for lQVIA, discusses ensuring fairness while using AI in clinical trials, the value of digital twins and the necessity of building and consistently adapting frameworks around AI use.
Davidi Vortman, CEO of UltraSight, discusses the company's AI-driven cardiac-imaging technology that helps providers quickly and efficiently triage patients and the ways the FDA-cleared system is used in the U.S. and globally.
Dr. Nele Jessel, chief medical officer at Athenahealth, discusses how bringing behavioral health tools, such as telehealth, into the primary care setting can improve access to services and reduce the stigma around mental health conditions.
Embark on the AI journey with a bold mindset, says Sunil Dadlani, Atlantic Health System's chief information and digital officer (and CISO). Still, review the technology and address the risks upfront to ensure proper guardrails for safety.
Dr Mohammad Adib Khumaidi, president of the Indonesian Medical Association, says industry collaboration is necessary during this "new technologic era" to further digital adoption and improve the medical provider and patient experience.
The partners will initially launch in two clinics in Texas to provide patients with ALS access to virtual-first specialty care providers, including respiratory therapists.
Jeremy Petch, director of digital health innovation at Hamilton Health Sciences, highlights how he and fellow panelists will explore potential solutions to problems posed by AI in healthcare at the HIMSS upcoming AI conference.
Identifying unusual behavior internally is crucial, says Dan Draper, founder and CEO of CipherStash. Encryption-in-use technology can help providers by protecting data and ensuring security for individual, sensitive records.
Dr Han Deok-Hyun, vice CMIO of Samsung Medical Center's Office of Digital Transformation, discusses how the APAC hospital received Stage 6 HIMSS AMAM and why it helps solidify its vision of providing state-of-the-art patient care.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.